Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?

Hasan Shemirani,Ali Hosseini
DOI: https://doi.org/10.4103/jrms.jrms_136_21
2024-02-02
Journal of Research in Medical Sciences
Abstract:Contrast-induced nephropathy (CIN) or contrast-induced acute kidney injury (CI-AKI) is an acute deterioration of renal function after the contrast medium administration. It is associated with increased mortality, hospital stay, prehospitalization, hemodialysis, and longtime mortality in patients undergoing coronary angiography (CAG) and percutaneous coronary intervention (PCI). There is no consensus on CIN definition, prevention, and treatment. Data are contradictory depending on the definition utilized on the biomarkers used to evaluate renal function and the timing of measurements. Consequently, the reported incidence of the condition varies among studies. CI-AKI was defined using either CI-AKI Network (serum creatinine [Scr] ≥0.3 mg/dL or 50%) or traditional (Scr ≥0.5 mg/dL or 25%) criteria in patients with baseline Scr levels <1.5 mg/dL (in about 90% of all patients). [ 1 ]
medicine, general & internal
What problem does this paper attempt to address?